Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE.
ARNUITY ELLIPTA vs AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Azelastine is a histamine H1-receptor antagonist that inhibits histamine release from mast cells; fluticasone propionate is a corticosteroid that suppresses inflammatory mediators including cytokines, prostaglandins, and leukotrienes, reducing nasal inflammation.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
1 spray per nostril twice daily (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per spray).
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Azelastine: ~25 hours (range 22-27 h). Fluticasone propionate: ~7.8 hours intranasal; 7-8 hours IV; context: intranasal dosing achieves steady-state in 1-2 weeks.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Azelastine: 75% renal (as unchanged drug and metabolites), 25% fecal. Fluticasone propionate: primarily fecal after IV (90%), renal <5%; after intranasal, significant first-pass hepatic metabolism to inactive metabolites excreted in bile and feces.
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid